{
    "id": 3611,
    "fullName": "FGFR2 K660E",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 K660E (corresponds to K659E in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K660E results in increased phosphorylation of Fgfr2, activation of downstream signaling, and is transforming in cell culture (PMID: 23786770).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "K660E",
    "createDate": "03/09/2015",
    "updateDate": "05/26/2019",
    "referenceTranscriptCoordinates": {
        "id": 90173,
        "transcript": "NM_022970",
        "gDna": "chr10:g.121488002T>C",
        "cDna": "c.1978A>G",
        "protein": "p.K660E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13137,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23908597).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13132,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8399,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 K660E in culture (PMID: 28978721).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6640,
                    "pubMedId": null,
                    "title": "PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/1249"
                },
                {
                    "id": 10753,
                    "pubMedId": 28978721,
                    "title": "The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13136,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3283,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response when treated with PD173074 (PMID: 23908597).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2590,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2 K660E were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13121,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 3413,
                "profileName": "FGFR2 K660E"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3413,
            "profileName": "FGFR2 K660E",
            "profileTreatmentApproaches": [
                {
                    "id": 7464,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 K660E"
                },
                {
                    "id": 7465,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 K660E"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 90174,
            "transcript": "NM_001144913",
            "gDna": "chr10:g.121488002T>C",
            "cDna": "c.1978A>G",
            "protein": "p.K660E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90173,
            "transcript": "NM_022970",
            "gDna": "chr10:g.121488002T>C",
            "cDna": "c.1978A>G",
            "protein": "p.K660E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}